Vertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 8,021 Shares

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 8,021 shares of the stock in a transaction dated Wednesday, April 5th. The shares were sold at an average price of $114.00, for a total transaction of $914,394.00. Following the completion of the sale, the chief marketing officer now owns 130,532 shares of the company’s stock, valued at approximately $14,880,648. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Monday, April 3rd, Jeffrey Chodakewitz sold 2,291 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $108.85, for a total transaction of $249,375.35.
  • On Wednesday, March 29th, Jeffrey Chodakewitz sold 13,750 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $106.65, for a total transaction of $1,466,437.50.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.67% during midday trading on Friday, hitting $116.47. 1,066,046 shares of the stock traded hands. The company’s market capitalization is $28.94 billion. The stock’s 50-day moving average price is $101.25 and its 200 day moving average price is $87.44. Vertex Pharmaceuticals Incorporated has a 52 week low of $71.46 and a 52 week high of $117.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, January 25th. The pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.06. Vertex Pharmaceuticals had a negative net margin of 6.76% and a negative return on equity of 2.15%. The business earned $458.71 million during the quarter, compared to analyst estimates of $453.40 million. During the same period last year, the firm posted $0.17 EPS. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post $1.62 EPS for the current year.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

TRADEMARK VIOLATION NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 8,021 Shares” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.chaffeybreeze.com/2017/04/21/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-cmo-sells-8021-shares-of-stock-updated.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its stake in Vertex Pharmaceuticals by 1.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,483,388 shares of the pharmaceutical company’s stock valued at $2,047,986,000 after buying an additional 235,525 shares during the period. Capital World Investors increased its stake in Vertex Pharmaceuticals by 2.8% in the third quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company’s stock valued at $1,944,119,000 after buying an additional 599,586 shares during the period. State Street Corp increased its stake in Vertex Pharmaceuticals by 2.7% in the fourth quarter. State Street Corp now owns 11,774,161 shares of the pharmaceutical company’s stock valued at $867,393,000 after buying an additional 308,574 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in Vertex Pharmaceuticals by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 6,492,221 shares of the pharmaceutical company’s stock valued at $566,187,000 after buying an additional 144,397 shares during the period. Finally, Jennison Associates LLC increased its stake in Vertex Pharmaceuticals by 74.2% in the third quarter. Jennison Associates LLC now owns 5,180,761 shares of the pharmaceutical company’s stock valued at $451,814,000 after buying an additional 2,205,961 shares during the period. 94.85% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on VRTX. Vetr lowered shares of Vertex Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $102.58 price target for the company. in a report on Thursday. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a report on Wednesday, April 12th. Credit Suisse Group AG reissued a “hold” rating and issued a $108.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, April 4th. HC Wainwright reaffirmed a “neutral” rating and issued a $85.00 price objective on shares of Vertex Pharmaceuticals in a research report on Sunday, April 2nd. Finally, JMP Securities reissued an “outperform” rating and set a $121.00 price target (up from $115.00) on shares of Vertex Pharmaceuticals in a research report on Friday, March 31st. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $108.31.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply